Company and Industry Overview * **Company**: Merck & Co., Inc. (NYSE:MRK) * **Industry**: Healthcare, Pharmaceuticals, Biotechnology Key Points GARDASIL * **Revenue Target**: Merck aims to achieve $11 billion in GARDASIL revenue by 2030, driven by international markets. * **International Expansion**: Merck focuses on increasing vaccine coverage rates, expanding coverage in NIPs, and targeting the private market and low middle-income segments. * **Manufacturing Capacity**: Merck has invested in manufacturing capacity to meet growing demand for GARDASIL, particularly in low middle-income markets. KEYTRUDA * **Growth Outlook**: KEYTRUDA is expected to see growth in 2024, driven by expansion into new tumor types and earlier treatment settings. * **Early-Stage Settings**: Early-stage KEYTRUDA is expected to be the primary driver of growth in 2024, with significant potential in triple-negative breast cancer and other tumor types. * **Subcutaneous Formulation**: Merck is exploring the subcutaneous formulation of KEYTRUDA for O-U.S. markets, aiming to improve patient convenience and access. Sotatercept * **PAH Approval**: Merck is confident in the approval of sotatercept for PAH in the EU and Japan, with a potential launch in the second half of 2024. * **Market Opportunity**: Sotatercept has the potential to become a significant revenue driver for Merck, with a target cardiovascular business of $15 billion by the mid-2030s. Vaccines * **Prevnar**: Merck is focused on expanding the Prevnar franchise, including the launch of VAXNEUVANCE for the pediatric segment and V116 for the adult segment. * **Dengue**: Merck is developing a dengue vaccine with potential for significant impact in the Southern Hemisphere and other regions. * **VAXELIS**: Merck is making steady progress with VAXELIS, a hexavalent vaccine covering multiple diseases. HIV * **Islatravir-Doravirine Combination**: Merck is developing an islatravir-doravirine combination for HIV, aiming to differentiate from existing treatments and address unmet needs. China * **Market Growth**: Merck has seen significant growth in China, driven by the launch of GARDASIL and other innovative products. * **Government Support**: The Chinese government's focus on improving healthcare standards and access has been beneficial for Merck. * **Partnerships**: Merck has formed partnerships with local companies to leverage the growing scientific ecosystem in China. Future Outlook * **Competitive Advantage**: Merck's competitive advantage lies in its pipeline of innovative products and its focus on patient care. * **Long-Term Growth**: Merck is focused on long-term growth, with a focus on expanding its pipeline and addressing unmet medical needs.

Verizon Communications Inc. (NYSE:VZ) Morgan Stanley Technology, Media & Telecom Conference March 5, 2024 11:45 AM ET Company Participants Tony Skiadas - Executive Vice President & CFO Conference Call Participants Simon Flannery - Morgan Stanley Simon Flannery All right. Good morning, everybody. Great pleasure to welcome Tony Skiadas from Verizon. Welcome, Tony. I think you have a safe harbor for us. Tony Skiadas Thanks, Simon, and good to be here. So before we get started, I need to draw your attention to ...

EPR Properties (NYSE:EPR) Citi's 2024 Global Property CEO Conference Call March 5, 2024 9:35 AM ET Company Participants Greg Silvers - Chairman and Chief Executive Officer Mark Peterson - Chief Financial Officer Greg Zimmerman - Chief Investment Officer Brian Moriarty - SVP of Corporate Communications Conference Call Participants Smedes Rose - Citi Research Smedes Rose Okay. Welcome to Citi’s 2024 Global Property CEO Conference. I am Smedes Rose with Citi Research. We are pleased to have with us EPR Proper ...

Datadog, Inc. (NASDAQ:DDOG) Morgan Stanley Technology, Media & Telecom Conference March 5, 2024 12:30 PM ET Company Participants Olivier Pomel - CEO David Obstler - CFO Conference Call Participants Sanjit Singh - Morgan Stanley Sanjit Singh All right. Good morning. We are here to talk Datadog and Observability. We have CEO, Olivier Pomel; and CFO, David Obstler. Olivier and David, thank you for coming to the TMT Conference once again. I think you've been here, I think, 3 or 4 years in a row now. So we reall ...

Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 44th Annual Health Care Conference March 5, 2024 12:50 PM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Welcome, and good afternoon, everyone. Welcome again to TD Cowen's 44th Annual Healthcare Conference, Day 2. My name is Tyler Van Buren, senior biotech analyst here. For our next session, very pleased to have a fireside chat with Gilead. And from Gilead, it's my pleasure ...

Plug Power Inc. (NASDAQ:PLUG) Special Call (Unlocking the Future: Hydrogen Mobility Fueling Solutions) March 5, 2024 12:00 PM ET Company Participants Meryl Fritz - Manager, Marketing & Communications Tim Lowrey - Director, Sales at Plug Cryo Adam Van De Mortel - Sales Engineering Manager Conference Call Participants Meryl Fritz All right, and I believe we're live. Hi everyone and welcome to this month's episode of Green Hydrogen with Plug. My name is Meryl and I'll be your moderator for today's session. In ...

Danaher Corporation (NYSE:DHR) TD Cowen 44th Annual Health Care Conference March 5, 2024 11:10 AM ET Company Participants Rainer Blair - President, CEO Conference Call Participants Dan Brennan - TD Cowen Dan Brennan Thank you. Dan Brennan from TD Cowen Life Science Tools Diagnostics. And we're here at 44th Annual Global Healthcare Conference. Really pleased to be joined here on the stage Rainer Blair, President and CEO of Danaher Corporation. So Rainer, thank you very much for being here. Rainer Blair Thank ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) TD Cowen 44th Annual Health Care Conference Call March 5, 2024 10:30 AM ET Company Participants David Altshuler - Executive Vice President, Research and Chief Scientific Officer Charlie Wagner - Executive Vice President and Chief Financial Officer Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I am Phil Nadeau, one of the biotech analysts, and it’s my pleas ...

Visa Inc. (NYSE:V) RBC Capital Markets Global Financial Institutions Conference March 5, 2024 12:15 PM ET Company Participants Ryan McInerney - President, CEO & Director Conference Call Participants Dave McKay - RBC Capital Markets Unidentified Company Representative Good afternoon. Please welcome to the stage Ryan McInerney, Chief Executive Officer at Visa, and Dave McKay, President and Chief Executive Officer, Royal Bank of Canada. Dave McKay Well, good afternoon, everybody. And it's great to be back agai ...

Simon Property Group, Inc. (NYSE:SPG) Citi's 2024 Global Property CEO Conference March 5, 2024 9:35 AM ET Company Participants David Simon – Chief Executive Officer Conference Call Participants Nick Joseph – Citigroup Craig Mailman – Citigroup Nick Joseph Welcome to Citi's 2024 Global Property CEO Conference. I'm Nick Joseph joined by Craig Mailman with Citi Research, and we are pleased to have with us Simon Property Group and CEO, David Simon. The session is for Citi clients only. If media or other individ ...